Formulate great-tasting fizzy tablets and powders

Manufacturers can now overcome challenges in effervescent dosage production with Beneo’s galenIQ 721 filler-binder. This excipient is easy to use and has improved technical properties.

PCR Savannah pharma banner
Orange vitamin c effervescent tablets in a tube (image: Shutterstock)

To improve the taste and stability of effervescent tablets and powders, Beneo presents galenIQ 721. The filler-binder meets current industry demands for patient-centric product development solutions, enabling pharma and nutraceutical manufacturers to develop patient-friendly products for those who have difficulty swallowing standard tablets. As a non-hygroscopic, water-soluble and directly compressible excipient, galenIQ 721 also provides high content uniformity and production efficiency for effervescent applications.

A convenient and appealing dosage form

Effervescent powders and tablets offer a more convenient way to deliver medicines or dietary supplements. They dissolve upon contact with water to release carbon dioxide and create a medicated drink. In addition, they can be used to formulate pharmaceuticals that are difficult to digest, cause stomach or oesophageal irritation or rely on a rapid onset of action, such as analgesics.

Overcoming manufacturing challenges

While the dosage form is highly convenient, manufacturing effervescents can be challenging. A non-hygroscopic, direct compression filler-binder such as galenIQ 721 is needed to produce highly stable tablets. This excipient ensures high content uniformity and facilitates production. It also has a sugar-like taste profile, a pleasant mouthfeel and can enhance the palatability of effervescent formulations. Available throughout Southern Africa from Savannah Fine Chemicals, galenIQ 721 is non-cariogenic, sweet and tooth friendly.

Enhanced product development

Dr Maj-Britt Cepok, head of business development, pharma, Beneo, comments: “Fizzy tablets are ideally suited to administer a wide range of light- and oxygen-sensitive active ingredients and those which require a large dose. In addition, effervescent preparations are more appealing to consumers than traditional dosage forms. galenIQ 721 helps manufacturers to tap into this market and enhance their development programmes.”

PCR Savannah pharma banner

Digital issue View Archive

Pharmaceutical & Cosmetic Review March 2023

In the March edition of P&C Review, we explore the evolution of clean beauty, 2023 fragrance trends, solutions for sustainable packaging and pharmaceutical excipients.

Visit the official COVID-19 government website to stay informed: